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Background: Inhibition of mitogen-activated protein kinase (MEK, also known as MAPK2, MAPKK), a key molecule
of the Ras/MAPK (mitogen-activated protein kinase) pathway, has shown promising effects on B-raf-mutated and
some RAS (rat sarcoma)-activated tumors in clinical trials. The objective of this study is to examine the efficacy of a
novel allosteric MEK inhibitor RO4987655 in K-ras-mutated human tumor xenograft models using [18F] FDG-PET
imaging and proteomics technology.
Methods: [18F] FDG uptake was studied in human lung carcinoma xenografts from day 0 to day 9 of RO4987655
therapy using microPET Focus 120 (CTI Concorde Microsystems, Knoxville, TN, USA). The expression levels of GLUT1
and hexokinase 1 were examined using semi-quantitative fluorescent immunohistochemistry (fIHC). The in vivo
effects of RO4987655 on MAPK/PI3K pathway components were assessed by reverse phase protein arrays (RPPA).
Results: We have observed modest metabolic decreases in tumor [18F] FDG uptake after MEK inhibition by
RO4987655 as early as 2 h post-treatment. The greatest [18F] FDG decreases were found on day 1, followed by a
rebound in [18F] FDG uptake on day 3 in parallel with decreasing tumor volumes. Molecular analysis of the tumors
by fIHC did not reveal statistically significant correlations of GLUT1 and hexokinase 1 expressions with the [18F] FDG
changes. RPPA signaling response profiling revealed not only down-regulation of pERK1/2, pMKK4, and pmTOR on
day 1 after RO4987655 treatment but also significant up-regulation of pMEK1/2, pMEK2, pC-RAF, and pAKT on day
3. The up-regulation of these markers is interpreted to be indicative of a reactivation of the MAPK and activation of
the compensatory PI3K pathway, which can also explain the rebound in [18F] FDG uptake following MEK inhibition
with RO4987655 in the K-ras-mutated human tumor xenografts.
Conclusions: We have performed the first preclinical evaluation of a new MEK inhibitor, RO4987655, using a
combination of [18F] FDG-PET imaging and molecular proteomics. These results provide support for using preclinical
[18F] FDG-PET imaging in early, non-invasive monitoring of the effects of MEK and perhaps other Ras/MAPK signaling
pathway inhibitors, which should facilitate a wider implementation of clinical [18F] FDG-PET to optimize their clinical use.
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The inhibition of integral components of the Ras/Raf/
mitogen-activated protein kinase kinase (MEK)/extracel-
lular signal-regulated kinase (ERK) signaling pathway
has been proven clinically effective in B-raf melanoma
and suggested to be effective in some RAS-activated tu-
mors [1,2]. MEK has a critical position in this pathway
with some direct upstream activators (e.g. Raf ) and some
downstream targets (e.g. ERK) and has been identified as
a promising target for selective inhibition of K-ras and
B-raf-mutated tumor types [3,4]. Many MEK inhibitors
have been developed and have entered preclinical effi-
cacy testing. Consequently, the need for new transla-
tional pharmacodynamic (PD) biomarkers for MEK
inhibition efficacy in cancer treatment is increasing.
Non-invasive positron emission tomography (PET)
imaging with the fluorine-18 labeled glucose analog
2-fluoro-2-deoxy-D-glucose ([18F] FDG) is being
used as a functional endpoint in phase I to III clinical tri-
als in oncology for assessing therapeutic response, in
addition to conventional endpoints such as toxicity in
tumor size. Fluorine-18-labeled glucose analog 2-fluoro-2-
deoxy-D-glucose-positron emission tomography ([18F]
FDG-PET) imaging has been used for monitoring neoadju-
vant chemotherapy in patients with locally advanced breast
cancer [5], non-small cell lung cancer [6], and lymphomas
[7], for an early prediction of response to imatinib mesylate
(GlivecTM) in patients with advanced soft tissue sarcoma
[8] and in the evaluation of vemurafenib (ZelborafTM),
an oral B-raf inhibitor [9]. Several recent phase I dose-
escalation clinical trials have also included [18F] FDG-
PET, for instance in assessing MEK inhibition as a
monotherapy or in combination with other drugs in
patients with advanced solid tumors [10-12].
PET imaging of small animals is increasingly used as a
translational efficacy biomarker in anti-cancer drug de-
velopment. Despite the inclusion of [18F] FDG-PET as a
possible clinical efficacy biomarker for MEK inhibition,
very few preclinical studies have yet been performed to
evaluate the nature and extent of its pharmacodynamic
and/or predictive capability. In addition, it is critical for
interpreting clinical data that the biological mechanisms
related to changes in [18F] FDG uptake are fully eluci-
dated, a task for which pre-clinical experimentations is
particularly well-suited. [18F] FDG-PET/CT and MRI
were used to show the synergistic effects of NVP-
BEZ235, a dual PI3K/mTOR inhibitor, with the MEK
inhibitor selumetinib in K-ras-mutated lung adenocar-
cinoma xenografts [10,13] and of the combination of
PI3K/mTOR inhibitor PE-04691502 and MEK inhibitor
PD0325901 in a mouse model of ovarian cancer [14].
Metabolic [18F] FDG-PET responses could also monitor
combination therapy with docetaxel and the MEK inhibi-
tor selumetinib in mice with lung cancer [15]. Recently,[18F] FDG-PET was used as an early PD biomarker of the
efficacy of MEK inhibitor RO5126766 in human colorectal
cancer xenografts with K-ras and B-raf mutations [16]. It
was shown to be a sensitive biomarker not only for pre-
dicting efficacy but also acquired resistance in B-rafV600
mutant melanoma xenografts in mice treated with vemur-
afenib alone and in combination with the MEK inhibitor
GDC-0973 [17].
Reverse phase protein array (RPPA) analysis is a high
throughput antibody-based technology for large-scale
analyses and quantitative assessments of activated signal-
ing pathways and identification of biomarkers [18,19].
Multiplex analyses of PD biomarkers by RPPA have been
performed in vitro in cancer cell lines [20,21] as well as
in cancer tissue and blood samples [22-24] in order to
assess response to target inhibition.
The MEK inhibitor RO4987655/CH4987655 (Hoffmann-
La Roche/Chugai Pharmaceutical, Tokyo, Japan) is
an orally active small molecule targeting mitogen-
activated protein kinase (MAP2K or MEK) with potent
anti-tumor activity [25]. RO4987655 binds to and in-
hibits MEK1, which results in the inhibition of MEK-
dependent cell signaling and tumor cell proliferation.
A phase I study of RO4987655 demonstrated its prom-
ising anti-tumor activity, which was further investi-
gated in specific populations of patients with RAS and/
or RAF mutation-driven tumors. [18F] FDG-PET im-
aging was included in the clinical efficacy assessments.
Reduction in tumor [18F] FDG uptake between base-
line and day 15 was observed in 79.4% of patients with
advanced solid tumors [10].
To examine the molecular basis for using [18F] FDG as
a PD biomarker for an early response to MEK inhibition,
we have here performed longitudinal [18F] FDG-PET im-
aging of metabolic responses to RO4987655 therapy in
human lung carcinoma xenografts. The expression levels
of the glucose transporter (GLUT1) and the activity of
hexokinase 1, which have been shown to be related to
[18F] FDG uptake in human cancer [26], were examined
using semi-quantitative fluorescent immunohistochemis-
try (fIHC). RPPA was used to assess RO4987655 effects
on the MAPK/PI3K pathway components in order to
make correlations with the metabolic changes deter-
mined in the tumors by [18F] FDG-PET.
Methods
Cell culture and reagents
The human lung adenocarcinoma cell line NCI-H2122
was purchased from the American Type Culture Collec-
tion (ATCC). All cells were maintained in the designated
media and indicated concentrations of heat-inactivated
fetal bovine serum (Gibco, Langley, OK, USA) and
L-glutamine (Sigma, St. Louis, MO, USA) according to
the ATCC recommendations. Cells were grown at 37°C
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3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-(3-oxo-1,2-
oxazinan-2-ylmethyl)benzohydroxamic acid 2-hydroxyethyl
ester, was synthesized by Chugai Pharmaceuticals Co.,
Ltd. The RO4987655 chemical structure is provided in
Additional file 1. For in vivo use, the drug was dissolved
in 50% ethanol/50% Cremophor® EL (Sigma) and stored
at −20°C. The vehicle and RO4987655 stock solutions
for in vivo experiments were diluted fivefold with distilled
water on each dosing day.
Cell proliferation and assay and Western blotting
Cells were treated with various concentrations of
RO4987655 for 72 h in 96-well plates and viable cells were
quantified with Cell Counting Kit-8 (Dojindo Molecular
Technologies, Inc, Rockville, MD, USA). For Western
blotting, cells were treated with RO4987655 for in-
dicated periods and lysed with cell lysis buffer (Cell
Signaling Technology, Beverly, MA, USA) containing a
protease inhibitor cocktail (cOmplete, EDTA-free, Roche,
Deutschland, Germany), phosphatase inhibitor cocktails 2
and 3 (Sigma), and 1 mM PMSF (Sigma). For detection of
protein bands, the following were used as primary anti-
bodies: pEGFR (Y1068, Cell Signaling Technology, 20234S),
EGFR (Cell Signaling Technology, 20234S), pMKK4
(S257/T261, Cell Signaling Technology, #9156), MKK4
(SEK1(5C10), Cell Signaling Technology, #3346), pAKT
(S473, Cell Signaling Technology, 9271), AKT (Cell
Signaling Technology, 9272), pERK (T202/Y204, Cell
Signaling Technology, 9101), ERK (Cell Signaling Technol-
ogy, 9102), pMEK1/2 (S217/S221, Cell Signaling Technology,
9121), MEK (Cell Signaling Technology, 9122), Cyclin D1
(NeoMarkers, RB-010-P0), and actin (Santa Cruz, sc-1616).
All protein bands were visualized with secondary anti-
bodies labeled with HRP and ECL system (GE Healthcare,
Wilmington, MA, USA) by using ImageQuant LAS 4000
(GE Healthcare).
Synthesis of [18F] FDG
[18F] FDG was obtained as an aliquot from daily clinical
production at the Karolinska University Hospital and was
subjected to all quality tests performed for administration
in humans. Identity and radiochemical purity were deter-
mined using radio-thin layer chromatography and radio-
liquid chromatography analyses prior to release.
Xenograft tumor models
Female athymic nude mice Balb nu/nu, age 5 to 6 weeks
(18 to 22 g) were purchased from NOVA/SCB (Sollentuna,
Sweden) and Charles River Lab International, Inc. (New
York, NY, USA). Animal care, handling, and health moni-
toring were carried out in accordance with the Guidelines
for Accommodation and Care of Laboratory Animals. All
animal experiments were performed in accordance withprotocols approved by the institutional animal care com-
mittee. NCI-H2122 cells (4 × 106/mouse) were inoculated
subcutaneously in the right flank of Balb-nu/nu mice.
Once tumors were established (100 to 200 mm3), mice
were randomized into groups with similar mean tumor
volumes at the start of the study. Tumor volume and
body weight were measured on days 0 (baseline), 1, 2, 3,
and 9 of [18F] FDG-PET imaging. Tumor growth inhib-
ition was calculated using the following formula: TGI =
[1 − (T − T0) / (C − C0)] × 100, where T and T0 are the
mean tumor volumes on specific experimental day and
on the first day of the treatment, respectively, for the
experimental groups and likewise, where C and C0 are
the mean tumor volumes for the control groups. The
daily administration was selected on preliminary screen-
ing studies and was lower than the maximal tolerated
dose (MTD), defined as the maximum dose associated
with <20% weight loss and no toxic deaths.
PET imaging
Further details on the PET imaging are provided in Additional
file 2. A time interval of 20 to 24 h was used between daily
RO4987655 administration and completion of PET im-
aging for each tumor-bearing mouse and for each PET im-
aging time point (day 0, 1, 3 and 9). Mice were fasted for 6
to 8 h prior to start of the imaging session. [18F] FDG (7
to 8 MBq per mouse, maximum volume of 200 μL) was
administered to awake, warmed (37°C) mice by a bolus in-
jection via the tail vein. Forty to sixty minutes after the
tracer injection, the mice were administered with isoflur-
ane, controlled by an E-Z anesthesia vaporizer (5% initially
and then 1.5% to maintain anesthesia, blended with 7:3
air/O2 and delivered through a Microflex non-rebreathing
mask from Euthanex Corporation, Palmer, PA, USA). The
mice were placed on a heated pad (37°C) on the camera
bed, with most of the body volume in the field of view
(7.68 cm). Emission data were collected for 20 min in list
mode with a microPET Focus 120 scanner (CTI Concorde
Microsystems). Maximum standardized uptake values
(SUVmax) of [
18F] FDG uptake in the tumor were calcu-
lated and normalized to the administered activity (MBq/
body weight, g). The drug effect on tumor metabolism
was estimated as%SUVmax change to day 0 (baseline).
Fluorescent immunohistochemistry (fIHC)
Further details on the fluorescent immunohistochemis-
try (fIHC) are provided in Additional file 2. Tumors
were collected for fIHC analyses 20–22 h after daily
RO4987655 administration for each [18F] FDG-PET time
point (days 0, 1, 3 and 9). For fIHC, tumor samples were
fixed by immersion for 24 h in a solution of 4% parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.4) contain-
ing phosphatase inhibitors. Tissue blocks containing 4
to5 tumor samples of different treatment groups were
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mounted on Superfrost Plus slides. Single- and multi-
labeling experiments were performed as described previ-
ously [27]. Briefly, sections were incubated with rabbit
anti-GLUT1 (Abcam, AB653, dilution 1:300) and anti-
hexokinase 1 (Abcam, AB65069, dilution 1:200) antibodies
and were visualized by incubation with Alexa488 conju-
gated donkey anti-rabbit antibody. Whole slide images
were captured on a Metasystems Vslide system (Newton,
MA, USA) equipped with appropriate filter sets using a ×
10 objective. Channel grey scale images were analyzed
using ImageJ software (1.45p NIH, Bethesda, MD, USA)
and GLUT1 and hexokinase 1 fluorescence intensity were
measured from 50 randomly selected spots within each
tumor sample. Supporting quantification figure is available
as an additional information (Additional file 3).
Reverse phase protein arrays
Tumors were collected for RPPA analyses 20 to 22 h after
daily RO4987655 administration for each [18F] FDG-PET
time point (days 0, 1, 3, and 9). Histological examination
of 15-μm thick frozen sections revealed good morphology
of tissues, with 75% to 90% vital tumor content (10% to
25% fibrosis, no necrosis). Tumor extracts of all samples
were prepared using 100 μL of lysis buffer CLB1 for
30 min at room temperature. Protein concentrations of ly-
sates were determined by Bradford Assay (Coomassie
Plus-The better Bradford™ Assay, Thermo Scientific, Wal-
tham, MA, USA). For the production of RPPA chips, the
tumor lysates were adjusted to 3 mg/ml protein concen-
tration in CLB1 buffer and subsequently diluted tenfold
with printing buffer CSBL1. The lysates were printed onto
Zeptosens chips (Bayer Technology Services GmbH,
Leverkusen, Germany) using a Gesim NP2.0 Nanoplotter
(GeSiM, Grosserkmannsdorf, Germany) and single droplet
deposition of lysate (0.4 nL per sample spot). Lysate sam-
ples were printed at four serial dilutions (start concentra-
tion 0.3 mg/mL, plus 1.6-fold dilutions), each dilution
as duplicate spots (in total eight spots per sample). Array
images and data were analyzed with the software Zepto-
VIEW 3.1 (Zeptosens, Witterswil, Switzerland).
The list of signaling proteins representing MAPK/PI3K/
glycolic pathways and included in the RPPA analyses is
provided in Additional file 4 for day 1 and in Additional
file 5 for day 3 of the RO4987655 treatment. RPPA ana-
lyses were performed at the NMI Natural and Medical
Sciences Institute, Reutlingen, Germany. The Ingenuity
pathway analysis, a web-based software application, was
used for comparison of MAPK/PI3K pathway modula-
tions on days 1 and 3 of RO4987655 treatment.
Statistical analysis
For the comparison of [18F] FDG-PET data, a pair-wise
t test with Tukey-Kramer correction for multiple testingwas applied using the software JMP (Version 10, © 2012
SAS Institute Inc., Cary, NC, USA). For the analysis of
the relationship of dose level and biomarker data from
both RPPA and fIHC, a statistical model based on a least
squares fit including the factors dose and dose2 was im-
plemented using the software JMP (Version 10, © 2012
SAS Institute Inc.).
Results
In vitro effects of RO4987655 on MAPK/AKT pathway
components in NCI-H2122 cells
Prior to in vivo studies, the efficacy of the RO4987655
treatment against NCI-H2122 cells was tested in vitro.
RO4987655 at doses ranging from 0.1 to 1.0 μM sup-
pressed pERK1/2 already at 2 h after the start of treat-
ment. Modest increases of pMEK and pAKT levels were
observed at this time point (Figure 1a). The drug treat-
ment over the time course at 0.1 μM of RO4987655
demonstrated transient decreases in pERK1/2, pMKK4,
and cyclin D1 expressions on day 1, followed by their
slight up-regulation on day 3. Since RO4987655 is a se-
lective MEK inhibitor [25], it had no influence on
pEGFR and pMEK at 6 h after the drug treatment, but,
similar to pERK1/2, pMKK4, and cyclin D1, pEGFR and
pMEK were up-regulated on day 3 (Figure 1b). This up-
regulation is known as a feedback reactivation of MAPK
pathway by selective MEK inhibitors in K-ras-mutated
cells [28]. Consistent with this signal blocking property
in NCI-H2122 cells, RO4987655 inhibited proliferation
of NCI-H2122 cells in a dose-dependent manner with
an IC50 value of 0.0065 μM (Figure 1c).
[18F] FDG-PET imaging in NCI-H2122 tumor xenografts,
harboring K-ras mutation, during RO4987655 treatment
The [18F] FDG-PET imaging studies in NCI-H2122 tumor
xenografts consisted of two experiments: the dose-ranging
(1.0 to 5.0 mg/kg) studies with imaging on days 0, 1, and 3
of treatment and the time course study of serial [18F]
FDG-PET scans at baseline and 2 h as well as days 1, 3,
and 9 of treatment with 2.5 mg/kg of RO4987655.
We first aimed to determine the earliest time-point of
the RO4987655 treatment response, detectable by [18F]
FDG-PET. Once tumor xenografts were established,
mice were randomized into study groups and the treat-
ment was initiated. The tumors size was estimated with
digital caliper and PET scans performed on days 0, 1,
and 3 with 1.0, 2.5, and 5.0 mg/kg RO4987655. The ve-
hicle treatment did not inhibit the NCI-H2122 tumor
xenograft growth over this time frame. In contrast,
RO4987655 treatment resulted in 119% tumor growth
inhibition (TGI) at 1.0 mg/kg, 145% TGI at 2.5 mg/kg
and 150% TGI at 5.0 mg/kg on day 3 (Figure 2a). PET
imaging showed that [18F] FDG uptake in the xenografts
decreased within 24 h (day 1) from the administration of
Figure 1 In vitro RO4987655 effects on MAPK/PI3K pathway in NCI-H2122 (K-ras) cells. (a) The cells were treated with indicated
concentrations of RO4987655 for 2 h. Cell lysates were analyzed by immunoblotting with antibodies to the phosphorylated versus total ERK1/2,
MEK1/2, and AKT. Actin was used as a loading control. (b) Time-dependent biomarker responses of NCI-H2122 cells to RO4987655 inhibition
(0.1 μM). (c) Dose-dependent anti-proliferative inhibition of RO4987655 in cells yielding a 50% inhibitory concentration (IC50) of 0.0065 μM.
Figure 2 Summary of the dose-ranging study (1.0 to 5.0 mg/kg) with [18F] FDG-PET imaging. (a) Anti-tumor activities of the RO4987655 in
NCI-H2122 tumor xenografted mice on days 0, 1 and 3 of the treatment. (b) Dose-and time-dependent FDG tumor uptake from day 0 (baseline)
to day 3 of the treatment. Analysis of SUVmax values between dose groups on day 1 (c) and day 3 (d) of the treatment.
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time- and dose-dependent rebound in uptake from day 1
to day 3, even though tumor growth inhibition contin-
ued on day 3 of the treatment (Figure 2b).
The PET data were analyzed for significant differences
between dose groups. On day 1 of the treatment, the
5.0 mg/kg group showed significantly lower [18F] FDG
uptake (*p = 0.0002) than that of the vehicle and 2.5 and
1.0 mg/kg groups (*p = 0.0253 and *p = 0.0103, respect-
ively) by a pairwise t test (Figure 2c). There were no sig-
nificant differences for SUVmax among the three dose
groups on day 3 (p = 0.24) (Figure 2d). After the last
PET scans, on day 3 of the treatment, the mice were
sacrificed and tumors were resected for further analyses.
Figure 3 (the upper panel) demonstrates representative
maximum intensity projection (MIP) PET images of nude
mice bearing NCI-H2122 tumor xenografts, scanned on
days 0, 1, and 3 after the treatment with vehicle (Figure 3a)
and RO4987655, 5.0 mg/kg (Figure 3c). The lower panel
shows corresponding transverse sections through a
plane of the mouse body that includes tumor (T) on days
0, 1, and 3 after vehicle (Figure 3b) and RO4987655
(5.0 mg/kg) (Figure 3d) treatment.
Our previous experiments with FDG distribution kin-
etics in Balb nu/nu mice demonstrated that tracer accu-
mulation in tumors reached its plateau in approximately
40 min after the tracer injection. Therefore, in this study,
PET scans were performed 40 to 50 min after the FDG
injection. The mice were physically active during FDG
accumulation period (40 to 50 min) before PET imaging;
therefore, physiological FDG uptake in brain, brown fat,
and muscles was observed on PET images, and tumors
were clearly distinct from surrounding tissues.
To extend the previous dose-ranging PET imaging ex-
periments, we added an acute (2 h post-treatment) and aFigure 3 The dose-ranging study (RO4987655, 1.0 to 5.0 mg/kg). Repr
Balb nu/nu mice, treated with vehicle and RO4987655 and scanned on day
MIP images (upper panel) and corresponding transaxial sections (lower pan
5.0 mg/kg treatment (c, d). The transaxial tumor sections (b, d) show a pla
was applied to all FDG-PET images after correction for injected dose per grlate (9 days after the treatment) [18F] FDG scan, in addition
to baseline, days 1 and 3 time points (six animals per group
at each time point) after single administration of 2.5 mg/kg
RO4987655 to NCI-H2122 xenografted mice. In the dose-
ranging study, treatment with RO4987655 5.0 mg/kg led to
dramatic decrease in FDG uptake on day 1 (Figure 3d) that
caused difficulties with tumor delineation on PET images.
Therefore, for the time course study, the RO4987655 dose
of 2.5 mg/kg was chosen.
Figure 4a demonstrates an example of one-mouse follow-
up [18F] FDG-PET MIP images, performed at day 0 (base-
line), 2 h, days 1, 3, and 9 after treatment with RO4987655.
Tumor locations are indicated with white circles. Figure 4b
shows corresponding transverse sections through a plane
of the mouse body that includes tumor (T).
The TGI results were similar to those obtained in the
dose-ranging studies, including treatment days 1 and 3.
Tumor volumes remained comparable between days 3
and 9 (Figure 4c). At the same time, we observed a de-
crease in [18F] FDG uptake in the tumors (15.4% change
compared to baseline) as early as 2 h after the start of
treatment. We continued with the daily RO4987655,
2.5 mg/kg treatment followed by PET examinations on
days 1, 3, and 9 of the drug administration. The max-
imum decrease was observed on day 1 (44% change,
with statistically significant differences compared to
baseline (*p < 0.05)), followed by a slight rebound on day
3 (33.6% change, *p < 0.05). The effect plateaued there-
after to day 9 of treatment. Serum glucose levels
remained comparable over these times (data not shown).
Fluorescence immunohistochemistry
In order to investigate the mechanism of the PET rebound
on day 3, we measured the status of molecular markers in
the xenografts. Levels of the [18F] FDG uptake markers,esentative [18F] FDG-PET images of NCI-H2122 tumors xenografted in
s 0, 1 and 3 after treatment. The one-mouse follow-up [18F] FDG-PET
el) performed on days 0, 1, and 3 after vehicle (a, b) and RO4987655,
ne of the mouse body that includes tumor (T). The same color scale
am tissue,% ID/gr, to show the relative [18F] FDG uptake in the tissues.
Figure 4 Summary of the time course study of serial [18F] FDG-PET imaging. (a) Representative one-mouse follow-up [18F] FDG-PET images,
performed at day 0 (baseline), 2 h, days 1, 3, and 9 after treatment with RO4987655, 2.5 mg/kg Tumor locations are indicated with the white
circle. (b) Corresponding transverse sections through a plane of the mouse body that includes tumor (T); PM, paraspinal muscle. (c) Comparison
of RO4987655, 2.5 mg/kg anti-tumor activities, and FDG-PET imaging results in NCI-H2122 tumor xenografted mice on day 0, after 2 h and days 1,
3, and 9 of the treatment (*p < 0.05, compared to baseline, day 0). The same color scale was applied to all FDG-PET images after correction for
injected dose per gram tissue,% ID/gr, to show the relative [18F] FDG uptake in the tissues.
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mors were visualized using immunofluorescence. Five
slides each containing 4 to 5 tumor samples of different
treatment groups (22 samples) were stained simultan-
eously and whole slides were scanned using × 10 primary
objective. Antibodies against hexokinase 1 and GLUT1
only labeled tumor cells and immunoreactivity could not
be detected in connective tissue (Figure 5a1 to a5 and 5c1
to c5). Hexokinase 1 immunoreactivity showed large vari-
ability within (core versus periphery) and among tumor
samples (data not shown). A comparison of average fluor-
escence intensity revealed modest increases in hexokinase
1 activity on day 3 of the RO4987655 treatment, althoughthe changes were not statistically significant in any of
the treatment groups compared to untreated controls
(Figure 5b). Inter-tumor variability for GLUT1 immu-
noreactivity was much lower compared to hexokinase 1
levels. Analysis of average GLUT1 immunoreactivity re-
vealed a gradual decrease in GLUT1 levels reaching sig-
nificance after 3 days treatment with a RO4987655 dose
of 5 mg/kg (Figure 5d).
In vivo effects of RO4987655 on MAPK/PI3K pathway
components assessed by RPPA
Responses of MAPK/PI3K/glycolytic signal transduction
pathways to RO4987655 inhibition (doses ranging from
Figure 5 Fluorescence immunohistochemistry results. Immunofluorescence micrographs, showing the distribution of hexokinase 1 (a1 to a5)
and GLUT1 (c1 to c5). Comparison of average fluorescence intensities in hexokinase 1 levels (b) and GLUT 1 expressions (d) among the
RO4987655 dose groups.
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on days 1 and 3 of the treatment after PET imaging.
The tumors were resected immediately after PET scans
(approximately 20 to 22 h after drug administration).
We found that 11 (Table 1) out of 50 investigated pro-
tein markers (Additional file 4) analyzed on days 1 and
10 (Table 2) out of 83 investigated protein markers
(Additional file 5) analyzed on day 3 of the RO4987655
treatment revealed significant dose-dependent modula-
tions. The Ingenuity Pathway Analysis (IPA) software
was used for mapping MAPK/PI3K pathways cascadeTable 1 The RPPA markers that showed significant
modulations after 1 day of the RO4987655 treatment
Analyte P value Pathway
Down-regulated
ERK1/2-P-Thr201/Tyr204 <0.001 MAPK












Cyclin D 0.0168 Cell cycle control
P53 0.0221 Cell cycle control
Akt-P-ser473 0.0991 Akt/metabolism
MEK2 0.6743 MAPK
C-met 0.8373 RTKphosphoproteins significantly modulated on day 1 (Figure 6a)
and day 3 (Figure 6b) of the treatment.
RPPA analysis showed dose-dependent modulations of
pERK1/2, pMKK4, and pEGFR with a strong reduction in
phosphorylated levels both on days 1 and 3 of the treat-
ment. In addition, after 1 day of treatment, MEK inhibition
resulted in not only significant dose-dependent down-
regulation of pmTOR (Table 1) but also up-regulation of
pC-RAF and reactivation of pMEK1/2, pMEK2, and pAKT
on day 3 of the treatment (Table 2). Cyclin D1 showed
enhanced expressions on both treatment days (Figure 7).
pAKT and pMEK2 were also up-regulated on day 1. How-
ever, this regulation was statistically significant only on day
3 of the treatment.
Discussion
We have recently reported the use of [18F] FDG-PET as
a PD biomarker for the efficacy of a first-in-class dualTable 2 The RPPA markers that showed significant
modulations after 3 days of the RO4987655 treatment









P53-P-Ser392 0.025 Cell cycle control
Cyclin D1 0.0302 Cell cycle control
C-Raf-P-Ser338 0.0371 MAPK
MEK2 0.0433 MAPK
Figure 6 (See legend on next page.)
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Figure 6 Ingenuity pathway analysis of the RO4987655 treatment effects on regulation of MAPK/PI3K/AKT pathway phospho-proteins.
(a) Day 1 and (b) day 3 of the treatment (colored markers for scores measured on the RPPA platform, green - negative and red - positive
dose-related regulation). The first column in the bar chat represents the regulation of the total protein, the second column the regulation of
the corresponding phospho-protein. In cases where more than one phospho sites were measured for the same protein, the third (and so forth)
column represents the regulation for the second (and so forth) phospho-protein. The grey nodes represent proteins where only the total proteins
were measured but no phosphorylated forms.
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B-raf mutant tumor xenografts models [16]. RO5126766
was designed to inhibit ERK signaling outputs more
effectively than standard MEK inhibitors [28]. The pre-
clinical [18F] FDG-PET results in tumor xenografts were
found to parallel the [18F] FDG-PET results obtained in
a phase I dose escalation study in humans [11]. The
novel allosteric MEK inhibitor RO4987655 studied here
binds and inhibits MEK, resulting in the suppression of
MEK-dependent cell signaling [25]. Both RO5126766
and RO4987655 have been assessed with [18F] FDG-PET
in phase I dose-escalation clinical trials and have shown
promising anti-tumor activities with strong decreases in
tumor metabolic responses [10,11]. Interestingly, the
[18F] FDG-PET data collected during these independent
studies led to different recommendations in the doses of
RO5126766 and RO4987655 for phase II [29].
To investigate further whether preclinical [18F] FDG-
PET imaging would also mirror the clinical observations
obtained for RO4987655, we performed longitudinal PET
scans of metabolic responses in K-ras-mutated NCI-
H2122 tumor xenografts in mice. Unlike the gradual re-
ductions in tumor [18F] FDG uptake by RO5126766 over
the treatment time, RO4987655 induced significant de-
creases in tumor metabolic activities already by day 1.
However, this decrease was followed by rapid dose-
dependent rebounds in the [18F] FDG uptake at day 3,Figure 7 RPPA results. Four markers that showed a significant dose effec
points for different animals along with a quadratic fit and the correspondineven though the drug was administered daily. To investi-
gate the mechanism for the [18F] FDG-PET response des-
pite continued TGI, we first examined whether the tumor
metabolic feedback activation in response to MEK inhib-
ition on day 3 correlated with GLUT1 and hexokinase 1,
using semi-quantitative fIHC. We found that the increase
in [18F] FDG uptake on day 3 was associated with elevated
hexokinase 1, which is consistent with studies reporting
that increased levels of hexokinases enhance [18F] FDG
intracellular trapping [30,31]. Furthermore, our observa-
tion was in agreement with several other studies that have
shown correlations of [18F] FDG uptake and hexokinase
expression in response to MEK inhibition [17]. However,
the hexokinase changes observed here were not statisti-
cally significant nor did changes in GLUT1 transporter ex-
pression significantly correlate with the observed [18F]
FDG changes. These results are mostly likely due to the
high intra- and inter-tumoral variability of GLUT1 and
hexokinase 1 expression in our IHC. No other significant
treatment effects were identifiable with this technique.
Previous studies have demonstrated that correlations be-
tween GLUT expressions and hexokinase activities and
[18F] FDG uptake are more pronounced at the cellular
level and have proposed that this could serve as a good
in vitro screening for testing the feasibility of cells to be
used in xenograft cancer models for PET imaging [16,32].
However, as discussed in [33-35] and also observed in ourt on both day 1 and day 3 are visualized showing the individual data
g confidence region.
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expected, most likely because [18F] FDG uptake in vivo
will depend on many factors: not only glucose trans-
porters, hexokinases, and glucose-6-phosphatase activities
but also the intra-tumoral cell density, blood supply, frac-
tion of hypoxic tissue, and viable cell numbers.
We also analyzed the effect of RO4987655 on specific cel-
lular signaling components. We showed in vitro (Figure 1)
that RO4987655 decreased pERK1/2 activities in tumor
cells followed by a pERK1/2 increase and up-regulated
phosphorylation of MEK, MAP2K4 (MKK4), and EGFR at
later time points. Also, a modest increase of pAKT, which
is a component of the alternative PI3K pathway involved in
cell survival signaling as well as glucose homeostasis regula-
tion, was observed. These results might indicate that NCI-
H2122 cells can be affected by a negative feedback upon
the MEK kinase inhibition.
RPPA proteomics technology was used to investigate
the molecular changes of the signaling status in vivo that
would influence the [18F] FDG uptake in NCI-H2122 tu-
mors upon treatment since it permits multiplex, highly
sensitive, and reproducible quantitative analysis of pro-
tein expression and phosphorylation levels. To our
knowledge, there are no previous reports in the litera-
ture that have combined preclinical [18F] FDG-PET with
RPPA for evaluating MEK inhibition efficacy.
In the xenograft experiment at 1.0, 2.5, and 5.0 mg/kg,
the significant pERK1/2 down-regulations revealed by
RPPA, both on day 1 and day 3 in all dose groups, con-
firmed that this MEK inhibitor clearly hits its target in
the xenografted tumors. These results support previous
publications proposing the inhibition of ERK phosphor-
ylation in tumors as a PD biomarker of MEK inhibition
[28,36,37]. RPPA also revealed significant reductions of
levels of pMKK4, a direct activator of MAP kinases in
response to various environmental stresses of mitogenic
stimuli [38], and of pEGFR, an upstream Ras activator,
on both treatment days (Tables 1 and 2).
In a recently published study, MEK inhibition in cancers
by RO4987655 was demonstrated by decreases in ERK1/2
phosphorylation [10]. Prior reports using RO4987655 with
B-raf-mutated HT-29 human colon cancer xenografts also
showed a marked reduction of pERK [25]. In addition, an
apparent relationship between [18F] FDG-PET data and
the degree of pERK suppression by RO4987655 in periph-
eral blood mononuclear cells of melanoma patients was
reported [29]. In this study, we observed different pERK1/
2 responses on day 3 in the in vivo and in vitro settings. In
our in vitro study at 0.1 μM of RO4987655, we observed
pERK1/2 up-regulation after initial down-regulation. This
is well known as a relief from a negative feedback on RAF
by MEK inhibition and is apparently due to feedback
regulation since there is no drug clearance. In contrast, in
our in vivo study, as revealed by RPPA, pERK1/2 wasclearly suppressed even on day 3 at all doses. In our previ-
ous study with B-raf-mutated HT-29 xenografts [25],
tumor pERK1/2 returned to the basal level after 24 h from
6.25 mg/kg RO4987655 administration due to the clear-
ance of the drug from blood in animals. In the current
study, we administered the drug daily and we resected the
tumors just after the drug administration. Therefore,
pERK1/2 down-regulation was observed even at day 3.
We also observed an up-regulation of pC-Raf and
pMEK1/2 on day 3 (Table 2), which is in agreement with
other reports [39] in which MEK inhibition led to an in-
crease in pMEK through feedback-mediated Ras activa-
tion. Interestingly, RO4987655 caused an activation of
cyclin D1, which was observed as early as day 1 of the
treatment. This increase can only be partly explained
by an activation of alternative pathways since the re-
activation of the MAPK pathway seems to be fully estab-
lished at day 3 that is 2 days later than the up-regulation
of cyclin D1 could be observed. As described by Rexer
et al. [40], the activation of alternative PI3K/AKT path-
ways limits the anti-tumor activity of MEK inhibitors and
down-regulation of cyclin D1 or reduced tumor cell prolif-
eration is not necessarily expected. Increased cyclin D1
expression in cells that showed resistance to MAPK inhib-
itors has been reported [41]. Thus, the activation of cyclin
D1 during the RO4987655 treatment may limit the inhibi-
tory effects of MEK inhibition on tumor growth.
In addition, as described above, the current study
found significantly increased phosphorylation of AKT on
day 3 of the RO4987655 treatment. Up-regulation of
pAKT may lead to the activation of the downstream sig-
nals that regulate glucose metabolism and cell survival.
Thus, there are two potential implications of the [18F]
FDG-PET rebound on day 3 of RO4987655 treatment:
up-regulating glucose uptake by activating AKT signal
and/or stimulating cell growth by reactivating the ERK/
MAPK pathway signal.
Concerning the direct up-regulation of glucose uptake
by activating AKT signaling, our initial investigation of
the expression levels of GLUT1 and hexokinase 1 in the
tumors with fIHC failed to identify any statistically sig-
nificant correlations between the [18F] FDG-PET re-
bound and protein expression. The expression profiling
of these proteins as well as other GLUT-family members
(for example, GLUT3) and hexokinase 2 in combination
with a more accurate quantitative approach needs to be
undertaken to clearly understand the correlations be-
tween [18F] FDG uptake and AKT signal activation by
MEK inhibition in K-ras-mutated tumors.
Concerning the indirect up-regulation of glucose up-
take by stimulating cell survival via AKT signaling, we
hypothesize that the rebound effect in response to MEK
inhibition by RO4987655 seen in the [18F] FDG-PET
analysis is due to activation of the PI3K/AKT mediated
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other MEK inhibitors, such as AZD6244 and HER2-
driven cancers [42], PD325901 in prostate cancer xeno-
grafts [43], and U0126 in a Wilms tumor model in mice
[44]. Interestingly, it was shown that dual blockage of
the compensatory PI3K/AKT/mTOR and RAS/MEK/
ERK pathways can synergistically inhibit tumor cell
growth in vitro and in vivo in different cancers [45-47];
combination treatment with MEK inhibitor AZD6244
and AKT inhibitor MK2206 was more effective than
each drug alone in lung cancer patients [48].
An indirect up-regulation of glucose uptake by stimu-
lating cell growth via reactivated ERK signaling is sup-
ported by a recent study with CH5126766 [28]. An
enormous suppression of ERK signal achieved maximal
tumor growth inhibition in both B-raf and K-ras xeno-
graft models. Thus, reactivation of ERK signal by relief
from the negative feedback to RAF may limit the anti-
tumor activity as well as [18F] FDG uptake at later
time points.
These results are important for the use of [18F] FDG-
PET imaging in clinical drug development and for un-
derstanding the mechanisms behind changes in [18F]
FDG uptake induced by MEK inhibitors. In a clinical set-
ting, a similar rebound in [18F] FDG uptake observed in
patients treated with MEK inhibitors may be useful for
detecting the development of drug resistance long before
increases in tumor size become detectable.
Conclusions
In this study, we have performed the first preclinical
evaluation of MEK efficacy in K-ras-mutated tumor xe-
nografts using a combination of molecular proteomics
and non-invasive [18F] FDG-PET imaging. The present
study demonstrates the following:
– [18F] FDG-PET revealed early transient metabolic
suppression in the tumors in response to
RO4987655
– MEK inhibition resulted in consistent pERK1/2
down-regulation in xenografts at all dose levels as
observed by RPPA
– Modulation of molecular markers such as pMEK1/2,
pC-Raf, pMKK4, pmTOR and pAKT suggested re-
activation of the MAPK pathway as well as activa-
tion of the compensatory PI3K pathway,
respectively. This may be causing the rebound in
FDG uptake observed following treatment with
RO4987655
The results obtained provide a strong rationale for com-
bining RO4987655 with compounds affecting the PI3K/
AKT pathway in order to overcome adaptive mechanisms
of tumor resistance to MEK inhibition.Additional files
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